Merck Animal Health, a division of Merck & Co., Inc. (MRK), has announced the expansion of its Nobivac NXT vaccine platform with the introduction of a new RNA-particle technology vaccine for feline leukemia virus. The newly USDA-approved vaccine will be available at veterinary clinics and hospitals nationwide this fall.
This innovative RNA-particle technology also underpins the Nobivac NXT Rabies and Nobivac NXT Canine Flu H3N2 vaccines, which were launched in June 2024.
As of the latest trading session, Merck's stock is priced at $115.87, reflecting a 0.26 percent increase on the New York Stock Exchange.